Chapter 10: Secondary Metabolites: Antibiotics & More

Secondary Metabolites: Antibiotics & More distinguishes secondary metabolites from primary ones by their specialized production during the stationary phase and explores a wide range of non-antibiotic applications, including anthracycline antitumor agents like doxorubicin, cholesterol-lowering statins like lovastatin, and immunosuppressants such as cyclosporin A and FK-506 used in organ transplantation. The content offers a deep dive into the pharmacology of major antibacterial classes, detailing how beta-lactams (penicillins, cephalosporins, carbapenems, and monobactams) inhibit peptidoglycan cell wall synthesis and how aminoglycosides, tetracyclines, and macrolides disrupt bacterial protein synthesis. A significant portion of the chapter analyzes the evolution of drug development, tracing the history of beta-lactams from natural penicillin G to semisynthetic generations designed to combat penicillinase-producing staphylococci and Gram-negative pathogens, as well as the engineering of aminoglycosides like amikacin to evade enzymatic inactivation. It further explains the genetic and physiological basis of antibiotic production, covering biosynthetic gene clusters, polyketide synthases, nonribosomal peptide synthetases, and the use of strain improvement techniques ranging from random mutagenesis to modern metabolic engineering. Finally, the chapter addresses the critical crisis of antibiotic resistance, outlining biochemical mechanisms such as target alteration, drug inactivation, and multidrug efflux pumps, while emphasizing the need for continued innovation through combinatorial chemistry and genomic approaches to discover new antimicrobial agents.